Evidence‑Based Management of Chronic Low‑Back Pain When NSAIDs and Acetaminophen Are Contraindicated

First‑Line Pharmacologic Therapy

• Duloxetine is the preferred first‑line medication for adults with chronic low‑back pain when NSAIDs are contraindicated and acetaminophen is declined; moderate‑quality evidence shows modest but clinically meaningful reductions in pain intensity and improvements in function. 1

Core Nonpharmacologic Interventions (Foundation of Care)

• The American College of Physicians strongly recommends initiating nonpharmacologic therapies (e.g., exercise, multidisciplinary rehabilitation, CBT) as the foundation of chronic low‑back pain management, providing benefits comparable to or greater than medication‑based approaches. Moderate‑quality evidence supports this recommendation. 2

• Exercise therapy (structured aerobic and strengthening programs) yields moderate‑quality evidence for both pain reduction and functional improvement in chronic low‑back pain. 2

• Multidisciplinary rehabilitation programs (combining physical therapy, education, and behavioral components) provide moderate‑quality evidence for comprehensive pain management and functional gains. 2

• Cognitive‑behavioral therapy (CBT) addresses psychosocial factors such as depression, catastrophizing, and fear‑avoidance beliefs that predict chronicity; moderate‑quality evidence supports its effectiveness. 2

• Mindfulness‑based stress reduction demonstrates moderate‑quality evidence for reducing chronic pain severity. 2

• Acupuncture offers moderate‑quality evidence of benefit for chronic low‑back pain. 2

• Spinal manipulation shows low‑quality evidence of possible benefit; may be considered when other therapies are insufficient. 2

• Massage therapy provides low‑quality evidence for short‑term symptom relief. 2

• Tai chi or yoga have low‑quality evidence suggesting they are reasonable adjunctive options for pain and function. 2

Second‑Line Pharmacologic Option

• Tramadol (25–50 mg every 6 h as needed, limited to 2–4 weeks) produces moderate‑quality evidence of short‑term pain relief and modest functional improvement compared with placebo when duloxetine response is inadequate after 4–6 weeks. 1

Opioid Therapy (Last‑Resort)

• Strong opioids (e.g., tapentadol, morphine, hydromorphone, oxymorphone) provide a small short‑term benefit (≈1‑point reduction on a 0–10 pain scale) with moderate‑quality evidence; use only for very severe, disabling pain after all other options have failed. 1

• Buprenorphine transdermal patches yield less than a 1‑point pain‑scale improvement; evidence is low‑quality, reinforcing their limited role. 1

• The modest clinical benefit of opioids must be weighed against significant risks including abuse, dependence, and adverse effects; they should not be used as first‑ or second‑line therapy. Moderate‑quality evidence supports this risk‑benefit caution. 1

Medications Demonstrating No Benefit (To Be Avoided)

• Tricyclic antidepressants and selective serotonin reuptake inhibitors show no difference from placebo in pain outcomes; moderate‑quality evidence indicates lack of efficacy. 1

• Systemic corticosteroids provide no benefit for chronic low‑back pain; moderate‑quality evidence confirms ineffectiveness. 1

• Benzodiazepines have limited evidence of short‑term benefit (e.g., tetrazepam at 5–7 days) but are not recommended for chronic use; evidence quality is low. 1

• Antiseizure medications (e.g., gabapentin, pregabalin) lack sufficient evidence for benefit in nonspecific chronic low‑back pain without radiculopathy; evidence is insufficient. 1

Key Clinical Recommendations

• Prioritize nonpharmacologic therapies as the core of management; they deliver comparable or superior outcomes to medications. Moderate‑quality evidence supports this approach. 2

• Reserve opioid therapy for severe, refractory cases only after comprehensive discussion of risks and benefits, and with close monitoring. Moderate‑quality evidence underlines this restriction. 1

• Limit duration of pharmacologic agents (duloxetine, tramadol, opioids) to the period where short‑term benefit is demonstrated, avoiding long‑term use without clear ongoing advantage.

• Address psychosocial contributors (depression, catastrophizing, fear‑avoidance, job dissatisfaction) through CBT or similar interventions, as they are predictive of chronicity.

• Avoid routine imaging in the absence of red‑flag symptoms, as it does not alter management for nonspecific chronic low‑back pain.

Management of Chronic Lower Back Pain Without NSAIDs

First-Line Pharmacologic Approach

• The American College of Physicians recommends duloxetine as a first-line alternative when NSAIDs are contraindicated, with moderate-quality evidence demonstrating modest but clinically meaningful effects on chronic low back pain 3, 4, 5
• Duloxetine should be started at 30 mg daily for one week to assess tolerability, then increased to 60 mg daily as the therapeutic dose 6, 7
• This SNRI antidepressant has a more favorable safety profile compared to tricyclic antidepressants, particularly in older adults 6
• Effects of duloxetine are sustained beyond the short-term (>4 weeks), unlike most other pharmacologic options 3, 4

Second-Line Options When Duloxetine Fails

• Tramadol achieves moderate short-term pain relief and small improvements in function compared to placebo, with moderate-quality evidence 5
• Tramadol has a dual mechanism (weak opioid + SNRI properties) providing analgesia without full opioid risks, but monitor for dizziness, confusion, constipation, and falls 6, 8
• Tramadol should be limited to 2-4 weeks while optimizing other therapies 8

Third-Line Options for Refractory Pain

• Opioids provide small short-term improvement (approximately 1 point on 0-10 pain scale) with moderate-quality evidence, but should be reserved for very severe, disabling pain in appropriately selected patients after all other options have failed 5, 9
• Gabapentin may be considered if neuropathic pain or radiculopathy is present, with evidence insufficient for pure nonspecific chronic low back pain without radicular symptoms 3, 4, 8

Essential Nonpharmacologic Therapies

• The American College of Physicians strongly recommends initiating nonpharmacologic therapies alongside any medication, including physical therapy and structured exercise programs, spinal manipulation, massage therapy, cognitive behavioral therapy, self-care education, and application of heat for short-term relief 5, 6, 7, 10
• Nonpharmacologic therapies provide comparable or superior benefits without medication risks 5, 6, 7, 10

Clinical Algorithm

• Start duloxetine 30 mg daily for one week, then increase to 60 mg daily, and simultaneously initiate physical therapy and exercise program 3, 4, 5, 6
• If inadequate response after 4-6 weeks, add tramadol 25-50 mg every 6 hours as needed (maximum 2-4 weeks) 5, 8
• If still inadequate and radicular symptoms present, add gabapentin titrated to therapeutic dose 8

Critical Monitoring Points

• Assess pain intensity (0-10 scale) and functional status at 2-4 weeks after initiating duloxetine, and monitor for duloxetine side effects: nausea, dry mouth, dizziness, constipation 6, 8
• Reassess need for continuation of all medications at 8-12 weeks, as most pharmacologic benefits are short-term 3, 4, 5